BioSpace News Archive

Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that given accelerating growth to later-stage development and the anticipated hiring and expansion of the Leadership Team, the Evelo Board of Directors has approved an inducement equity plan.

BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer and President, will present at the Goldman Sachs 42nd Annual Healthcare Conference

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced it has entered into a strategic agreement with OrganX to develop clinical decision support tools across the transplant patient journey.

Invivoscribe, a global leader in precision diagnostics, announced the launch of a new 12-color multiparametric flow cytometry service in Shanghai, China, the newest reference laboratory in their international LabPMM network.

BioKansas, a non-profit organization supporting the bioscience industry has extended their partnership with the Biotechnology Innovation Organization for a second year.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, announced that senior management will participate in fireside chats at two upcoming virtual investor conferences

Medifast, Inc., the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, announced that its Board of Directors has declared a $1.42 quarterly cash dividend to its stockholders.

New Coverage Further Validates Laparoscopic Radiofrequency Ablation (Lap-RFA) as a Standard of Care for Uterine Fibroids

CooperCompanies announced financial results for its fiscal second quarter ended April 30, 2021.